The Scottish Medicines Consortium (SMC) has approved everolimus (Afinitor®) for use within NHS Scotland in the treatment of neuroendocrine pancreatic cancer in adults with progressive disease.
Pancreatic Cancer UK provided a joint patient submission with the NET Patient Foundation to the SMC in March 2012.
Neuroendocrine tumours that originate in the pancreas are rare, and it is estimated that five patients per year will be eligible for this treatment.
Alex Ford, Chief Executive, Pancreatic Cancer UK, comments, "We are very pleased that this treatment has been recommended for patients with neuroendocrine pancreatic cancer as it provides another treatment option for those with progressive disease."
View the full guidance from the SMC.